0001104659-23-045666.txt : 20230414 0001104659-23-045666.hdr.sgml : 20230414 20230414170018 ACCESSION NUMBER: 0001104659-23-045666 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 EFFECTIVENESS DATE: 20230414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-478980 FILM NUMBER: 23821883 BUSINESS ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 D 1 primary_doc.xml X0708 D LIVE 0001651407 Checkpoint Therapeutics, Inc. 95 SAWYER ROAD SUITE 110 WALTHAM MA MASSACHUSETTS 02453 781-652-4500 DELAWARE None None Corporation true James F. Oliviero, III 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Executive Officer Director Michael Weiss 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Garrett Gray 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Executive Officer Neil Herskowitz 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Barry Salzman 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Christian Bechon 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Lindsay A. Rosenwald 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Scott Boilen 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Biotechnology Decline to Disclose 06b false 2023-03-30 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE NEW YORK NY NEW YORK 10022 CA CALIFORNIA FL FLORIDA IL ILLINOIS NJ NEW JERSEY NY NEW YORK false Indefinite 0 Indefinite In connection with the sale of $6,120,000 of common stock Checkpoint issued warrants pursuant to Rule 506(b) for up to 3,400,000 shares of common stock and placement agent warrants exercisable for 102,000 shares of common stock. false 9 0 0 Checkpoint Therapeutics, Inc. paid $0 in connection with the warrants offered pursuant to Rule 506(b). Checkpoint Therapeutics, Inc. paid approximately $428,400 in fees and expenses in connection to the sale of common stock in a concurrent offering. 0 false Checkpoint Therapeutics, Inc. /s/ James F. Oliviero James F. Oliviero President and Chief Executive Officer 2023-04-14